POT1 and glioma: POT1 germline mutations have been described in high risk families with melanoma [17, 18], colorectal cancer [19], glioma [20], and chronic lymphocytic leukemia [21], and in KDR in Hodgkin lymphoma families [22], and demonstrate that family-based NGS approaches work likewise in cancer.